Drug Database
Ref. Compounds
Structure Search
Hot Search： Flibanserin | Cariprazine | Rolapitant | Xuriden | Rolapitant Hydrochloride Hydrate

Home> Latest Approval >Indication >Main Body

  • Latest Approval

U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

2016-02-09 15:59
Indication
Bristol-Myers Squibb Company
Read：244 Favorite  0
  Share
相关阅读
You may interest

Copyright©2020 药渡经纬信息科技（北京）有限公司 电子与信息服务业务经营许可证151001号

京ICP备14047345| 京公安网备11010802017043号 |（京）-经营性-2015-0023（互联网药品信息服务资格证书）

药渡APP Drug A-Z
药渡APP
药渡微信二维码
微信二维码